UCrest Berhad Releases Q4 and Full Year 2026 Results: Revenue Declines, Strategic AI Launch Ahead

Key Financial Highlights

• Revenue Decline: UCrest Berhad reported a significant drop in revenue for the financial year ended 31 May 2026, with total revenue falling to RM13.96 million, compared to RM18.44 million in the previous year. The current quarter revenue was RM4.26 million, down from RM4.66 million a year ago.
• Net Profit and Loss: The Group posted a net loss attributable to owners of the company of RM0.617 million for the current quarter, a reversal from a profit of RM1.664 million in the same quarter last year. For the full year, net profit stood at RM0.269 million, sharply down from RM5.167 million in the preceding year.
• Gross Profit Margins: Gross profit for the year declined to RM2.25 million from RM3.25 million, reflecting tighter margins amid lower revenue and persistent cost pressures.
• Earnings Per Share: Basic and diluted earnings per share for the current quarter both registered at a loss of 0.08 sen, compared to an earning of 0.22 sen per share in the previous year. For the full year, EPS dropped to 0.04 sen from 0.69 sen.
• Cash and Liquidity: The Group’s cash and equivalents dropped sharply to RM9.31 million from RM17.54 million a year earlier, following significant investments in intangible assets and a net outflow from operations.
• Foreign Exchange: The company faced a foreign currency translation loss of RM2.61 million for the year, which negatively impacted total comprehensive income.

Operational and Strategic Developments

• iMedic Platform & AI Launch: UCrest is focusing on the advancement and scaling of its flagship iMedic platform, with the official release of a medical-focused AI Large Language Model (LLM) planned. This new platform is expected to significantly enhance diagnostic accuracy, clinical risk assessment, and personalized treatment planning, supporting the delivery of preventive, predictive, precision, and participative medicine.
• Healthcare E-Commerce Expansion: The Group is actively operationalizing e-commerce capabilities within its healthcare platform, aiming to diversify revenue streams by onboarding more healthcare merchants and broadening medical and wellness offerings. However, management notes that success in this segment will depend on user adoption, market competition, and industry conditions.
• Longevity Solutions Exploration: Preliminary engagement in the longevity-focused healthcare solutions market has shown some interest, although it is still in early stages and not yet contributing materially to financial results.

Balance Sheet and Capital Structure

• Total Assets: Total assets stood at RM47.67 million as of 31 May 2026, down from RM50.97 million. Notably, intangible assets jumped to RM5.04 million from RM1.24 million, reflecting increased investment in technology development.
• Net Asset Value: Net assets per share remained steady at 6 sen.
• Equity and Reserves: Share capital remained unchanged at RM56.97 million, with total equity at RM41.97 million, down from RM44.31 million, mainly due to accumulated losses and foreign currency translation deficits.
• No Dividends: No interim dividends were declared or proposed for the period under review.

Corporate Actions and Regulatory Updates

• Private Placement: The company obtained shareholder approval for a private placement of up to 74.38 million new ordinary shares (representing up to 10% of issued capital) at the AGM on 18 November 2024. Bursa Malaysia approved the listing and quotation of these shares, but as of the reporting date, no new shares have been issued. An extension was granted until 23 October 2026 to complete the placement exercise. This pending corporate action could impact share liquidity and ownership structure if executed.
• No Borrowings, Litigation, or Off-Balance-Sheet Items: The Group reported no borrowings, no material litigation, and no off-balance-sheet financial instruments.
• No Tax Provision: There was no tax provision for the current interim period, as the company remained in a loss position.

Factors of Interest to Shareholders and Potential Price Sensitivities

• Profitability Challenges: The sharp drop in revenue and reversal to a loss in the quarter may raise concerns about the Group’s near-term earnings visibility and growth trajectory. Persistent cost pressures and foreign exchange losses further erode profitability.
• Cash Burn and Investments: The significant decrease in cash reserves, primarily due to heavy investments in intangible assets, may signal both a bold technological pivot and near-term liquidity risk if not offset by revenue growth.
• AI Platform Launch: The upcoming launch of the AI Large Language Model for healthcare is a potentially transformative event that could materially impact future growth, customer engagement, and investor sentiment.
• Private Placement: The pending private placement, if executed, could dilute existing shareholders but also provide necessary capital for further expansion. Investors should monitor developments and terms closely.
• No Dividends: The absence of dividend payments underscores the company’s reinvestment focus and cash preservation strategy.

Management Outlook and Guidance

The Board views the Group’s prospects as stable but recognizes risks from economic conditions, regulatory changes, and execution challenges. Management remains focused on disciplined cost management, platform conversion improvements, and leveraging the upcoming AI-driven enhancements to drive value. No official profit guidance or forecast has been issued.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and seek professional advice before making any investment decisions. The information herein is based on unaudited financial statements and may be subject to change or revision.

Laporan Kewangan UCrest Berhad: Penurunan Pendapatan, Pelancaran AI Kesihatan Bakal Datang

Sorotan Kewangan Utama

• Pendapatan Menurun: UCrest Berhad melaporkan penurunan besar dalam pendapatan tahun kewangan berakhir 31 Mei 2026, iaitu RM13.96 juta berbanding RM18.44 juta tahun sebelumnya. Pendapatan suku semasa juga menurun kepada RM4.26 juta daripada RM4.66 juta.
• Untung/Rugi Bersih: Syarikat mencatat kerugian bersih RM0.617 juta untuk suku semasa berbanding untung RM1.664 juta setahun lalu. Secara tahunan, untung bersih hanya RM0.269 juta, menurun drastik dari RM5.167 juta.
• Margin Untung Kasar: Untung kasar setahun jatuh ke RM2.25 juta daripada RM3.25 juta, menandakan margin semakin ketat dalam suasana kos yang meningkat dan pendapatan menurun.
• Pendapatan Sesaham: EPS asas dan dicairkan masing-masing rugi 0.08 sen untuk suku semasa, berbanding untung 0.22 sen tahun lalu. Bagi setahun penuh, EPS turun ke 0.04 sen daripada 0.69 sen.
• Tunai dan Kecairan: Tunai dan setara tunai jatuh mendadak ke RM9.31 juta daripada RM17.54 juta, sebahagian besar akibat pelaburan besar dalam aset tak ketara dan aliran keluar operasi.
• Kadar Tukaran Asing: Syarikat mengalami kerugian terjemahan mata wang asing RM2.61 juta untuk tahun tersebut, menjejaskan pendapatan komprehensif keseluruhan.

Perkembangan Operasi dan Strategik

• Platform iMedic & Pelancaran AI: Fokus utama UCrest adalah memajukan dan menskalakan platform iMedic, dengan pelancaran rasmi model AI Large Language Model (LLM) untuk perubatan. Platform ini dijangka meningkatkan ketepatan diagnosis, penilaian risiko klinikal, dan perancangan rawatan tersuai.
• Pembangunan E-Dagang Kesihatan: Syarikat aktif memperluas fungsi e-dagang dalam platform kesihatan untuk mempelbagaikan pendapatan melalui penambahan peniaga baharu dan perkhidmatan perubatan serta kesihatan yang lebih meluas. Namun, kejayaan bergantung kepada kadar penerimaan pengguna dan persaingan pasaran.
• Solusi Longevity: Penyertaan awal dalam pasaran solusi longevity menunjukkan beberapa minat, namun masih di peringkat awal dan belum menyumbang ketara kepada hasil kewangan.

Kedudukan Kewangan dan Struktur Modal

• Jumlah Aset: Jumlah aset berjumlah RM47.67 juta pada 31 Mei 2026, turun dari RM50.97 juta. Aset tak ketara meningkat ketara ke RM5.04 juta daripada RM1.24 juta, mencerminkan pelaburan dalam pembangunan teknologi.
• Nilai Aset Bersih: Nilai aset bersih sesaham kekal pada 6 sen.
• Ekuiti dan Rizab: Modal saham tidak berubah pada RM56.97 juta, dengan jumlah ekuiti RM41.97 juta (menurun dari RM44.31 juta) akibat kerugian terkumpul dan defisit terjemahan mata wang.
• Tiada Dividen: Tiada dividen interim diisytiharkan atau dicadangkan untuk tempoh ini.

Tindakan Korporat & Kemas Kini Regulasi

• Penempatan Saham Persendirian: Syarikat mendapat kelulusan pemegang saham untuk penempatan saham persendirian sehingga 74.38 juta saham baharu (tidak melebihi 10% modal diterbitkan) pada AGM 18 November 2024. Bursa Malaysia telah meluluskan penyenaraian saham-saham ini tetapi sehingga kini tiada saham baharu diterbitkan. Lanjutan masa diberikan sehingga 23 Oktober 2026 untuk melengkapkan penempatan ini. Jika diteruskan, ini berpotensi memberi kesan kepada kecairan dan struktur pemilikan saham.
• Tiada Pinjaman, Litigasi atau Instrumen Luar Imbangan: Syarikat tiada pinjaman, tiada litigasi material, dan tiada instrumen kewangan luar imbangan.
• Tiada Cukai Diperuntukkan: Tiada peruntukan cukai dibuat untuk tempoh interim, memandangkan syarikat berada dalam kedudukan rugi.

Perkara Penting untuk Pemegang Saham & Sensitiviti Harga

• Cabaran Keuntungan: Penurunan pendapatan mendadak dan beralih kepada kerugian suku ini mungkin menimbulkan kebimbangan tentang pertumbuhan dan kejelasan keuntungan syarikat dalam masa terdekat.
• Pengurangan Tunai & Pelaburan: Penurunan besar dalam rizab tunai akibat pelaburan dalam aset tak ketara menandakan peralihan teknologi yang agresif namun juga risiko kecairan jika tidak diimbangi pertumbuhan hasil.
• Pelancaran AI Platform: Pelancaran AI untuk kesihatan dijangka menjadi pemangkin pertumbuhan masa depan dan boleh mempengaruhi sentimen pelabur.
• Penempatan Saham Persendirian: Jika diteruskan, ia boleh mencairkan pegangan saham sedia ada tetapi juga memberikan modal untuk pengembangan lanjut.
• Tiada Dividen: Ketiadaan pembayaran dividen mencerminkan fokus syarikat pada pelaburan semula dan pemeliharaan tunai.

Prospek & Panduan Pengurusan

Lembaga Pengarah percaya prospek syarikat kekal stabil tetapi perlu berhati-hati terhadap risiko ekonomi, regulatori dan pelaksanaan. Fokus pengurusan adalah pada kawalan kos, penambahbaikan platform dan pelaksanaan strategi AI. Tiada panduan untung rasmi dikeluarkan.

Penafian

Artikel ini untuk tujuan maklumat sahaja dan bukan nasihat pelaburan. Pelabur dinasihatkan menilai keadaan sendiri dan mendapatkan nasihat profesional sebelum membuat keputusan pelaburan. Maklumat berdasarkan penyata kewangan belum diaudit dan mungkin berubah.

View UCREST BERHAD Historical chart here